<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>microRNAs (miRNAs) are small, non-coding <z:chebi fb="40" ids="33697">RNA</z:chebi> molecules that regulate gene expression by targeting specific <z:chebi fb="2" ids="33699">mRNAs</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>microRNAs play a role in several physiological processes in the cell, including migration, proliferation, differentiation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Apart from their role in regular metabolism, abnormal profiles of miRNA expression accompany <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> transformation, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>microRNAs may play a role in each phase of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> including <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, invasion, intravasation, circulation, extravasation and metastatic colonization </plain></SENT>
<SENT sid="4" pm="."><plain>microRNA levels may serve as a predictive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> marker, which was confirmed by the serum level of miR-29a targeting KLF4, a marker of cell stemness, and the plasma level of miR-221 down-regulating c-Kit, Stat5A and ETS1, which are signal transducers and transcription factor, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In turn, the level of miR-143 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells decreasing the amount of MACC1 (<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-associated in <z:hpo ids='HP_0003003'>colon cancer</z:hpo>-1) and oncogenic KRAS protein, may be utilized as a prognostic marker </plain></SENT>
<SENT sid="6" pm="."><plain>Also, single nucleotide polymorphisms of genes encoding miRNAs, including miR-423 and miR-608, which correlate with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence, may be useful as diagnostic, prognostic and predictive indicators in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Pre-miR-34a and pre-miR-199a decreased the level of Axl, a tyrosine-protein kinase receptor, so they can be considered as drugs in antimetastatic therapy </plain></SENT>
<SENT sid="8" pm="."><plain>On the other hand, miR-222 targeting ADAM-17, a disintegrin and metalloproteinase, and miR-328 interacting with ABCG2, an ABC transporter, may overcome drug resistance of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>microRNAs may be considered in wide-range application to facilitate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> diagnosis, prognosis, prediction and therapy, however, further clinical, epidemiological and in vitro studies should be conducted to verify their utility </plain></SENT>
</text></document>